The Experts below are selected from a list of 1296 Experts worldwide ranked by ideXlab platform

C Jakob - One of the best experts on this subject based on the ideXlab platform.

  • Incorporation of the Bone Marker Carboxy-Terminal Telopeptide of Type-1 Collagen (ICTP) into a Combined ISS-ICTP Score Improves the Prognostic Significance of the ISS in Newly Diagnosed Symptomatic Multiple Myeloma and Identifies a Very Low Risk Grou
    Blood, 2008
    Co-Authors: C Jakob, J Sterz, P Liebisch, J Rademacher, U Heider, C Fleissner, M Kaiser, Christian Müller, Orhan Sezer
    Abstract:

    The prognosis of patients with newly diagnosed symptomatic multiple myeloma (MM) has been improved, but the outcome is still highly variable. Several prognostic markers, including parameters of tumor burden and cytogenetics were adopted to identify high-risk patients. Recently the International Staging System (ISS), including the parameters β2-microglobulin (β2M) and albumin, was introduced for patients with symptomatic MM. In previous studies the bone resorption marker Carboxy-Terminal Telopeptide of type-1 collagen (ICTP) was identified as a sensitive and specific marker of increased bone resorption and as a strong prognostic factor for overall survival (OS) in MM. Since bone disease is a hallmark of MM, we investigated the prognostic impact of the bone resorption marker ICTP in combination with ISS, β2M, albumin and deletion of chromosome 13 (del(13q14)) and high-dose therapy (HDT) in 100 patients with newly diagnosed symptomatic MM. β2M alone, albumin alone, ISS, del(13q14) and ICTP were significant prognostic factors for overall survival. In contrast to ICTP, lytic bone lesions were not an independent prognostic factor for OS ( P =0.289). In a multivariate analysis, ICTP was the most powerful prognostic factor (log rank P

  • incorporation of the bone marker Carboxy Terminal Telopeptide of type 1 collagen ictp into a combined iss ictp score improves the prognostic significance of the iss in newly diagnosed symptomatic multiple myeloma and identifies a very low risk group
    Blood, 2008
    Co-Authors: C Jakob, J Sterz, P Liebisch, J Rademacher, U Heider, C Fleissner, M Kaiser, Christian Müller, Orhan Sezer
    Abstract:

    The prognosis of patients with newly diagnosed symptomatic multiple myeloma (MM) has been improved, but the outcome is still highly variable. Several prognostic markers, including parameters of tumor burden and cytogenetics were adopted to identify high-risk patients. Recently the International Staging System (ISS), including the parameters β2-microglobulin (β2M) and albumin, was introduced for patients with symptomatic MM. In previous studies the bone resorption marker Carboxy-Terminal Telopeptide of type-1 collagen (ICTP) was identified as a sensitive and specific marker of increased bone resorption and as a strong prognostic factor for overall survival (OS) in MM. Since bone disease is a hallmark of MM, we investigated the prognostic impact of the bone resorption marker ICTP in combination with ISS, β2M, albumin and deletion of chromosome 13 (del(13q14)) and high-dose therapy (HDT) in 100 patients with newly diagnosed symptomatic MM. β2M alone, albumin alone, ISS, del(13q14) and ICTP were significant prognostic factors for overall survival. In contrast to ICTP, lytic bone lesions were not an independent prognostic factor for OS ( P =0.289). In a multivariate analysis, ICTP was the most powerful prognostic factor (log rank P <0.001, hazard-ratio: 9-fold increase). Furthermore ICTP clearly separated two subgroups with a good and a worse prognosis within each of the three ISS stages (ISS I: P =0.027, ISS II: P =0.022, ISS III: P =0.013). A combined ISS-ICTP score, including β2M (cut off: 3.5 mg/l), albumin (cut off: < 3.5 g/dl) and ICTP (cut off: reference limit) significantly ( P <0.001) separated four risk groups with a 5-year overall survival rate of 94% in the very low risk group, 65% in the low risk group, 46% in the intermediate risk group and 22% in the high risk group, respectively. In the very low risk group, there was no significant survival benefit with highdose therapy ( P =0.24), while HDT was a favorable prognostic factor in ISS-ICTP risk groups 1–3 ( P =0.037, P =0.011 and P =0.012) and in ISS stages I–III ( P =0.026, P =0.001 and P =0.052). These data demonstrate that the inclusion of the bone resorption marker ICTP adds to the prognostic value of ISS and may have clinical implications for selection of HDT in frontline treatment strategies in newly diagnosed MM. Table: Comparison between ISS and combined ISS-ICTP score in newly diagnosed symptomatic MM. | Combined ISS-ICTP Score | | ISS | |:-----------------------:| --------------------------------------------------------------------- | ----------- | --------------------------------------- | | Risk factors† (group) | Patients (%) | 5-yr OS (%) | | Stage* | Patients (%) | 5-yr OS (%) | | 0 (very low) | 21 | 94 | | | | | | 1 (low) | 38 | 64 | | I | 38 | 72 | | 2 (intermediate) | 26 | 46 | | II | 35 | 62 | | 3 (high) | 15 | 22 | | III | 27 | 35 | | † risk factors: | β2M ≥3.5 mg/l Albumin <3.5 g/dl ICTP >reference limit | * | ISS I: ISS II: ISS III: | β2M <3.5 mg/l, Albumin ≥3.5 g/dl not stage I or III β2M ≥5.5 mg/l |

  • Incorporation of the bone marker Carboxy-Terminal Telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma
    Leukemia, 2008
    Co-Authors: C Jakob, J Sterz, P Liebisch, M Mieth, J Rademacher, A Goerke, U Heider, C Fleissner, M Kaiser, I Von Metzler
    Abstract:

    Several prognostic markers, including parameters of tumor burden and cytogenetics, were adopted to identify high-risk patients in multiple myeloma (MM). Recently, the International Staging System (ISS), including β2-microglobulin (β2M) and albumin, was introduced for patients with symptomatic MM. As bone disease is a hallmark of MM, we investigated the prognostic impact of the bone resorption marker Carboxy-Terminal Telopeptide of type-1 collagen (ICTP) in combination with ISS, β2M, albumin, deletion of chromosome 13 and high-dose therapy (HDT) in 100 patients with newly diagnosed symptomatic MM. β2M alone, albumin alone, ISS, HDT, del(13q14) and ICTP were significant prognostic factors for overall survival (OS). In a multivariate analysis, ICTP was the most powerful prognostic factor (log-rank P

  • incorporation of the bone marker Carboxy Terminal Telopeptide of type 1 collagen improves prognostic information of the international staging system in newly diagnosed symptomatic multiple myeloma
    Leukemia, 2008
    Co-Authors: C Jakob, J Sterz, P Liebisch, M Mieth, J Rademacher, A Goerke, U Heider, C Fleissner, M Kaiser, I Von Metzler
    Abstract:

    Several prognostic markers, including parameters of tumor burden and cytogenetics, were adopted to identify high-risk patients in multiple myeloma (MM). Recently, the International Staging System (ISS), including β2-microglobulin (β2M) and albumin, was introduced for patients with symptomatic MM. As bone disease is a hallmark of MM, we investigated the prognostic impact of the bone resorption marker Carboxy-Terminal Telopeptide of type-1 collagen (ICTP) in combination with ISS, β2M, albumin, deletion of chromosome 13 and high-dose therapy (HDT) in 100 patients with newly diagnosed symptomatic MM. β2M alone, albumin alone, ISS, HDT, del(13q14) and ICTP were significant prognostic factors for overall survival (OS). In a multivariate analysis, ICTP was the most powerful prognostic factor (log-rank P<0.001, hazard ratio: ninefold increase). ICTP clearly separated two subgroups with a good and a worse prognosis within each of the three ISS stages (ISS I: P=0.027, ISS II: P=0.022, ISS III: P=0.013). Incorporation of ICTP in a combined ICTP-ISS score significantly (P<0.001) separated four risk groups with a 5-year OS rate of 95, 65, 46 and 32%, respectively. These data demonstrate for the first time that the inclusion of the collagen-I degradation product ICTP, as a biomarker of bone resorption, adds to the prognostic value of ISS.

  • bone resorption parameters Carboxy Terminal Telopeptide of type i collagen ictp amino Terminal collagen type i Telopeptide ntx and deoxypyridinoline dpd in mgus and multiple myeloma
    European Journal of Haematology, 2002
    Co-Authors: C Jakob, U Heider, Ivana Zavrski, Brigitte Brux, Jan Eucker, Corinna Langelotz, Pranav Sinha, Kurt Possinger, Orhan Sezer
    Abstract:

    Skeletal morbidity is a major problem in multiple myeloma. Histomorphometric studies have demonstrated that increased bone resorption can be present even in the absence of radiographic abnormalities. To overcome diagnostic problems in estimating the activity of bone resorption, new laboratory parameters that reflect bone metabolism accurately are urgently needed. We analyzed three parameters of osteoclastic bone destruction, i.e. deoxypyridinoline (Dpd) and amino-Terminal collagen type-I Telopeptide (NTx) in urine and Carboxy-Terminal Telopeptide of type-I collagen (ICTP) in serum, of 75 patients with multiple myeloma (n = 57) or monoclonal gammopathy of undetermined significance (MGUS, n = 18) by ELISA/RIA techniques. Serum ICTP and urinary Dpd levels increased parallel to the stage of the disease and differed significantly (P < 0.001 for ICTP and P = 0.03 for Dpd) between MGUS, myeloma stage I, and myeloma in stages II and III according to Salmon and Durie. ICTP and Dpd were significantly elevated in patients with multiple myeloma in stage I compared to individuals with MGUS, while no significant difference was found for NTx. In this first study comparing the prognostic relevance of ICTP, NTx, and Dpd in multiple myeloma patients, ICTP was found to be a prognostic factor for overall survival in the Kaplan-Meier analysis (log-rank test: P < 0.03). Urinary NTx showed borderline significance (P = 0.05), and Dpd had no prognostic value in the survival analysis. Our data show that serum ICTP and urinary Dpd levels increase in parallel to advanced disease stages, and gives the first report on a significant difference in the bone resorption parameters ICTP and Dpd between individuals with MGUS and patients with myeloma in stage I. Among the bone resorption parameters studied serum ICTP was found to be the best prognostic factor for survival in multiple myeloma.

U Heider - One of the best experts on this subject based on the ideXlab platform.

  • Incorporation of the Bone Marker Carboxy-Terminal Telopeptide of Type-1 Collagen (ICTP) into a Combined ISS-ICTP Score Improves the Prognostic Significance of the ISS in Newly Diagnosed Symptomatic Multiple Myeloma and Identifies a Very Low Risk Grou
    Blood, 2008
    Co-Authors: C Jakob, J Sterz, P Liebisch, J Rademacher, U Heider, C Fleissner, M Kaiser, Christian Müller, Orhan Sezer
    Abstract:

    The prognosis of patients with newly diagnosed symptomatic multiple myeloma (MM) has been improved, but the outcome is still highly variable. Several prognostic markers, including parameters of tumor burden and cytogenetics were adopted to identify high-risk patients. Recently the International Staging System (ISS), including the parameters β2-microglobulin (β2M) and albumin, was introduced for patients with symptomatic MM. In previous studies the bone resorption marker Carboxy-Terminal Telopeptide of type-1 collagen (ICTP) was identified as a sensitive and specific marker of increased bone resorption and as a strong prognostic factor for overall survival (OS) in MM. Since bone disease is a hallmark of MM, we investigated the prognostic impact of the bone resorption marker ICTP in combination with ISS, β2M, albumin and deletion of chromosome 13 (del(13q14)) and high-dose therapy (HDT) in 100 patients with newly diagnosed symptomatic MM. β2M alone, albumin alone, ISS, del(13q14) and ICTP were significant prognostic factors for overall survival. In contrast to ICTP, lytic bone lesions were not an independent prognostic factor for OS ( P =0.289). In a multivariate analysis, ICTP was the most powerful prognostic factor (log rank P

  • incorporation of the bone marker Carboxy Terminal Telopeptide of type 1 collagen ictp into a combined iss ictp score improves the prognostic significance of the iss in newly diagnosed symptomatic multiple myeloma and identifies a very low risk group
    Blood, 2008
    Co-Authors: C Jakob, J Sterz, P Liebisch, J Rademacher, U Heider, C Fleissner, M Kaiser, Christian Müller, Orhan Sezer
    Abstract:

    The prognosis of patients with newly diagnosed symptomatic multiple myeloma (MM) has been improved, but the outcome is still highly variable. Several prognostic markers, including parameters of tumor burden and cytogenetics were adopted to identify high-risk patients. Recently the International Staging System (ISS), including the parameters β2-microglobulin (β2M) and albumin, was introduced for patients with symptomatic MM. In previous studies the bone resorption marker Carboxy-Terminal Telopeptide of type-1 collagen (ICTP) was identified as a sensitive and specific marker of increased bone resorption and as a strong prognostic factor for overall survival (OS) in MM. Since bone disease is a hallmark of MM, we investigated the prognostic impact of the bone resorption marker ICTP in combination with ISS, β2M, albumin and deletion of chromosome 13 (del(13q14)) and high-dose therapy (HDT) in 100 patients with newly diagnosed symptomatic MM. β2M alone, albumin alone, ISS, del(13q14) and ICTP were significant prognostic factors for overall survival. In contrast to ICTP, lytic bone lesions were not an independent prognostic factor for OS ( P =0.289). In a multivariate analysis, ICTP was the most powerful prognostic factor (log rank P <0.001, hazard-ratio: 9-fold increase). Furthermore ICTP clearly separated two subgroups with a good and a worse prognosis within each of the three ISS stages (ISS I: P =0.027, ISS II: P =0.022, ISS III: P =0.013). A combined ISS-ICTP score, including β2M (cut off: 3.5 mg/l), albumin (cut off: < 3.5 g/dl) and ICTP (cut off: reference limit) significantly ( P <0.001) separated four risk groups with a 5-year overall survival rate of 94% in the very low risk group, 65% in the low risk group, 46% in the intermediate risk group and 22% in the high risk group, respectively. In the very low risk group, there was no significant survival benefit with highdose therapy ( P =0.24), while HDT was a favorable prognostic factor in ISS-ICTP risk groups 1–3 ( P =0.037, P =0.011 and P =0.012) and in ISS stages I–III ( P =0.026, P =0.001 and P =0.052). These data demonstrate that the inclusion of the bone resorption marker ICTP adds to the prognostic value of ISS and may have clinical implications for selection of HDT in frontline treatment strategies in newly diagnosed MM. Table: Comparison between ISS and combined ISS-ICTP score in newly diagnosed symptomatic MM. | Combined ISS-ICTP Score | | ISS | |:-----------------------:| --------------------------------------------------------------------- | ----------- | --------------------------------------- | | Risk factors† (group) | Patients (%) | 5-yr OS (%) | | Stage* | Patients (%) | 5-yr OS (%) | | 0 (very low) | 21 | 94 | | | | | | 1 (low) | 38 | 64 | | I | 38 | 72 | | 2 (intermediate) | 26 | 46 | | II | 35 | 62 | | 3 (high) | 15 | 22 | | III | 27 | 35 | | † risk factors: | β2M ≥3.5 mg/l Albumin <3.5 g/dl ICTP >reference limit | * | ISS I: ISS II: ISS III: | β2M <3.5 mg/l, Albumin ≥3.5 g/dl not stage I or III β2M ≥5.5 mg/l |

  • Incorporation of the bone marker Carboxy-Terminal Telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma
    Leukemia, 2008
    Co-Authors: C Jakob, J Sterz, P Liebisch, M Mieth, J Rademacher, A Goerke, U Heider, C Fleissner, M Kaiser, I Von Metzler
    Abstract:

    Several prognostic markers, including parameters of tumor burden and cytogenetics, were adopted to identify high-risk patients in multiple myeloma (MM). Recently, the International Staging System (ISS), including β2-microglobulin (β2M) and albumin, was introduced for patients with symptomatic MM. As bone disease is a hallmark of MM, we investigated the prognostic impact of the bone resorption marker Carboxy-Terminal Telopeptide of type-1 collagen (ICTP) in combination with ISS, β2M, albumin, deletion of chromosome 13 and high-dose therapy (HDT) in 100 patients with newly diagnosed symptomatic MM. β2M alone, albumin alone, ISS, HDT, del(13q14) and ICTP were significant prognostic factors for overall survival (OS). In a multivariate analysis, ICTP was the most powerful prognostic factor (log-rank P

  • incorporation of the bone marker Carboxy Terminal Telopeptide of type 1 collagen improves prognostic information of the international staging system in newly diagnosed symptomatic multiple myeloma
    Leukemia, 2008
    Co-Authors: C Jakob, J Sterz, P Liebisch, M Mieth, J Rademacher, A Goerke, U Heider, C Fleissner, M Kaiser, I Von Metzler
    Abstract:

    Several prognostic markers, including parameters of tumor burden and cytogenetics, were adopted to identify high-risk patients in multiple myeloma (MM). Recently, the International Staging System (ISS), including β2-microglobulin (β2M) and albumin, was introduced for patients with symptomatic MM. As bone disease is a hallmark of MM, we investigated the prognostic impact of the bone resorption marker Carboxy-Terminal Telopeptide of type-1 collagen (ICTP) in combination with ISS, β2M, albumin, deletion of chromosome 13 and high-dose therapy (HDT) in 100 patients with newly diagnosed symptomatic MM. β2M alone, albumin alone, ISS, HDT, del(13q14) and ICTP were significant prognostic factors for overall survival (OS). In a multivariate analysis, ICTP was the most powerful prognostic factor (log-rank P<0.001, hazard ratio: ninefold increase). ICTP clearly separated two subgroups with a good and a worse prognosis within each of the three ISS stages (ISS I: P=0.027, ISS II: P=0.022, ISS III: P=0.013). Incorporation of ICTP in a combined ICTP-ISS score significantly (P<0.001) separated four risk groups with a 5-year OS rate of 95, 65, 46 and 32%, respectively. These data demonstrate for the first time that the inclusion of the collagen-I degradation product ICTP, as a biomarker of bone resorption, adds to the prognostic value of ISS.

  • bone resorption parameters Carboxy Terminal Telopeptide of type i collagen ictp amino Terminal collagen type i Telopeptide ntx and deoxypyridinoline dpd in mgus and multiple myeloma
    European Journal of Haematology, 2002
    Co-Authors: C Jakob, U Heider, Ivana Zavrski, Brigitte Brux, Jan Eucker, Corinna Langelotz, Pranav Sinha, Kurt Possinger, Orhan Sezer
    Abstract:

    Skeletal morbidity is a major problem in multiple myeloma. Histomorphometric studies have demonstrated that increased bone resorption can be present even in the absence of radiographic abnormalities. To overcome diagnostic problems in estimating the activity of bone resorption, new laboratory parameters that reflect bone metabolism accurately are urgently needed. We analyzed three parameters of osteoclastic bone destruction, i.e. deoxypyridinoline (Dpd) and amino-Terminal collagen type-I Telopeptide (NTx) in urine and Carboxy-Terminal Telopeptide of type-I collagen (ICTP) in serum, of 75 patients with multiple myeloma (n = 57) or monoclonal gammopathy of undetermined significance (MGUS, n = 18) by ELISA/RIA techniques. Serum ICTP and urinary Dpd levels increased parallel to the stage of the disease and differed significantly (P < 0.001 for ICTP and P = 0.03 for Dpd) between MGUS, myeloma stage I, and myeloma in stages II and III according to Salmon and Durie. ICTP and Dpd were significantly elevated in patients with multiple myeloma in stage I compared to individuals with MGUS, while no significant difference was found for NTx. In this first study comparing the prognostic relevance of ICTP, NTx, and Dpd in multiple myeloma patients, ICTP was found to be a prognostic factor for overall survival in the Kaplan-Meier analysis (log-rank test: P < 0.03). Urinary NTx showed borderline significance (P = 0.05), and Dpd had no prognostic value in the survival analysis. Our data show that serum ICTP and urinary Dpd levels increase in parallel to advanced disease stages, and gives the first report on a significant difference in the bone resorption parameters ICTP and Dpd between individuals with MGUS and patients with myeloma in stage I. Among the bone resorption parameters studied serum ICTP was found to be the best prognostic factor for survival in multiple myeloma.

Orhan Sezer - One of the best experts on this subject based on the ideXlab platform.

  • Incorporation of the Bone Marker Carboxy-Terminal Telopeptide of Type-1 Collagen (ICTP) into a Combined ISS-ICTP Score Improves the Prognostic Significance of the ISS in Newly Diagnosed Symptomatic Multiple Myeloma and Identifies a Very Low Risk Grou
    Blood, 2008
    Co-Authors: C Jakob, J Sterz, P Liebisch, J Rademacher, U Heider, C Fleissner, M Kaiser, Christian Müller, Orhan Sezer
    Abstract:

    The prognosis of patients with newly diagnosed symptomatic multiple myeloma (MM) has been improved, but the outcome is still highly variable. Several prognostic markers, including parameters of tumor burden and cytogenetics were adopted to identify high-risk patients. Recently the International Staging System (ISS), including the parameters β2-microglobulin (β2M) and albumin, was introduced for patients with symptomatic MM. In previous studies the bone resorption marker Carboxy-Terminal Telopeptide of type-1 collagen (ICTP) was identified as a sensitive and specific marker of increased bone resorption and as a strong prognostic factor for overall survival (OS) in MM. Since bone disease is a hallmark of MM, we investigated the prognostic impact of the bone resorption marker ICTP in combination with ISS, β2M, albumin and deletion of chromosome 13 (del(13q14)) and high-dose therapy (HDT) in 100 patients with newly diagnosed symptomatic MM. β2M alone, albumin alone, ISS, del(13q14) and ICTP were significant prognostic factors for overall survival. In contrast to ICTP, lytic bone lesions were not an independent prognostic factor for OS ( P =0.289). In a multivariate analysis, ICTP was the most powerful prognostic factor (log rank P

  • incorporation of the bone marker Carboxy Terminal Telopeptide of type 1 collagen ictp into a combined iss ictp score improves the prognostic significance of the iss in newly diagnosed symptomatic multiple myeloma and identifies a very low risk group
    Blood, 2008
    Co-Authors: C Jakob, J Sterz, P Liebisch, J Rademacher, U Heider, C Fleissner, M Kaiser, Christian Müller, Orhan Sezer
    Abstract:

    The prognosis of patients with newly diagnosed symptomatic multiple myeloma (MM) has been improved, but the outcome is still highly variable. Several prognostic markers, including parameters of tumor burden and cytogenetics were adopted to identify high-risk patients. Recently the International Staging System (ISS), including the parameters β2-microglobulin (β2M) and albumin, was introduced for patients with symptomatic MM. In previous studies the bone resorption marker Carboxy-Terminal Telopeptide of type-1 collagen (ICTP) was identified as a sensitive and specific marker of increased bone resorption and as a strong prognostic factor for overall survival (OS) in MM. Since bone disease is a hallmark of MM, we investigated the prognostic impact of the bone resorption marker ICTP in combination with ISS, β2M, albumin and deletion of chromosome 13 (del(13q14)) and high-dose therapy (HDT) in 100 patients with newly diagnosed symptomatic MM. β2M alone, albumin alone, ISS, del(13q14) and ICTP were significant prognostic factors for overall survival. In contrast to ICTP, lytic bone lesions were not an independent prognostic factor for OS ( P =0.289). In a multivariate analysis, ICTP was the most powerful prognostic factor (log rank P <0.001, hazard-ratio: 9-fold increase). Furthermore ICTP clearly separated two subgroups with a good and a worse prognosis within each of the three ISS stages (ISS I: P =0.027, ISS II: P =0.022, ISS III: P =0.013). A combined ISS-ICTP score, including β2M (cut off: 3.5 mg/l), albumin (cut off: < 3.5 g/dl) and ICTP (cut off: reference limit) significantly ( P <0.001) separated four risk groups with a 5-year overall survival rate of 94% in the very low risk group, 65% in the low risk group, 46% in the intermediate risk group and 22% in the high risk group, respectively. In the very low risk group, there was no significant survival benefit with highdose therapy ( P =0.24), while HDT was a favorable prognostic factor in ISS-ICTP risk groups 1–3 ( P =0.037, P =0.011 and P =0.012) and in ISS stages I–III ( P =0.026, P =0.001 and P =0.052). These data demonstrate that the inclusion of the bone resorption marker ICTP adds to the prognostic value of ISS and may have clinical implications for selection of HDT in frontline treatment strategies in newly diagnosed MM. Table: Comparison between ISS and combined ISS-ICTP score in newly diagnosed symptomatic MM. | Combined ISS-ICTP Score | | ISS | |:-----------------------:| --------------------------------------------------------------------- | ----------- | --------------------------------------- | | Risk factors† (group) | Patients (%) | 5-yr OS (%) | | Stage* | Patients (%) | 5-yr OS (%) | | 0 (very low) | 21 | 94 | | | | | | 1 (low) | 38 | 64 | | I | 38 | 72 | | 2 (intermediate) | 26 | 46 | | II | 35 | 62 | | 3 (high) | 15 | 22 | | III | 27 | 35 | | † risk factors: | β2M ≥3.5 mg/l Albumin <3.5 g/dl ICTP >reference limit | * | ISS I: ISS II: ISS III: | β2M <3.5 mg/l, Albumin ≥3.5 g/dl not stage I or III β2M ≥5.5 mg/l |

  • bone resorption parameters Carboxy Terminal Telopeptide of type i collagen ictp amino Terminal collagen type i Telopeptide ntx and deoxypyridinoline dpd in mgus and multiple myeloma
    European Journal of Haematology, 2002
    Co-Authors: C Jakob, U Heider, Ivana Zavrski, Brigitte Brux, Jan Eucker, Corinna Langelotz, Pranav Sinha, Kurt Possinger, Orhan Sezer
    Abstract:

    Skeletal morbidity is a major problem in multiple myeloma. Histomorphometric studies have demonstrated that increased bone resorption can be present even in the absence of radiographic abnormalities. To overcome diagnostic problems in estimating the activity of bone resorption, new laboratory parameters that reflect bone metabolism accurately are urgently needed. We analyzed three parameters of osteoclastic bone destruction, i.e. deoxypyridinoline (Dpd) and amino-Terminal collagen type-I Telopeptide (NTx) in urine and Carboxy-Terminal Telopeptide of type-I collagen (ICTP) in serum, of 75 patients with multiple myeloma (n = 57) or monoclonal gammopathy of undetermined significance (MGUS, n = 18) by ELISA/RIA techniques. Serum ICTP and urinary Dpd levels increased parallel to the stage of the disease and differed significantly (P < 0.001 for ICTP and P = 0.03 for Dpd) between MGUS, myeloma stage I, and myeloma in stages II and III according to Salmon and Durie. ICTP and Dpd were significantly elevated in patients with multiple myeloma in stage I compared to individuals with MGUS, while no significant difference was found for NTx. In this first study comparing the prognostic relevance of ICTP, NTx, and Dpd in multiple myeloma patients, ICTP was found to be a prognostic factor for overall survival in the Kaplan-Meier analysis (log-rank test: P < 0.03). Urinary NTx showed borderline significance (P = 0.05), and Dpd had no prognostic value in the survival analysis. Our data show that serum ICTP and urinary Dpd levels increase in parallel to advanced disease stages, and gives the first report on a significant difference in the bone resorption parameters ICTP and Dpd between individuals with MGUS and patients with myeloma in stage I. Among the bone resorption parameters studied serum ICTP was found to be the best prognostic factor for survival in multiple myeloma.

  • Bone resorption parameters [Carboxy‐Terminal Telopeptide of type‐I collagen (ICTP), amino‐Terminal collagen type‐I Telopeptide (NTx), and deoxypyridinoline (Dpd)] in MGUS and multiple myeloma
    European journal of haematology, 2002
    Co-Authors: C Jakob, U Heider, Ivana Zavrski, Brigitte Brux, Jan Eucker, Corinna Langelotz, Pranav Sinha, Kurt Possinger, Orhan Sezer
    Abstract:

    Skeletal morbidity is a major problem in multiple myeloma. Histomorphometric studies have demonstrated that increased bone resorption can be present even in the absence of radiographic abnormalities. To overcome diagnostic problems in estimating the activity of bone resorption, new laboratory parameters that reflect bone metabolism accurately are urgently needed. We analyzed three parameters of osteoclastic bone destruction, i.e. deoxypyridinoline (Dpd) and amino-Terminal collagen type-I Telopeptide (NTx) in urine and Carboxy-Terminal Telopeptide of type-I collagen (ICTP) in serum, of 75 patients with multiple myeloma (n = 57) or monoclonal gammopathy of undetermined significance (MGUS, n = 18) by ELISA/RIA techniques. Serum ICTP and urinary Dpd levels increased parallel to the stage of the disease and differed significantly (P < 0.001 for ICTP and P = 0.03 for Dpd) between MGUS, myeloma stage I, and myeloma in stages II and III according to Salmon and Durie. ICTP and Dpd were significantly elevated in patients with multiple myeloma in stage I compared to individuals with MGUS, while no significant difference was found for NTx. In this first study comparing the prognostic relevance of ICTP, NTx, and Dpd in multiple myeloma patients, ICTP was found to be a prognostic factor for overall survival in the Kaplan-Meier analysis (log-rank test: P < 0.03). Urinary NTx showed borderline significance (P = 0.05), and Dpd had no prognostic value in the survival analysis. Our data show that serum ICTP and urinary Dpd levels increase in parallel to advanced disease stages, and gives the first report on a significant difference in the bone resorption parameters ICTP and Dpd between individuals with MGUS and patients with myeloma in stage I. Among the bone resorption parameters studied serum ICTP was found to be the best prognostic factor for survival in multiple myeloma.

I Von Metzler - One of the best experts on this subject based on the ideXlab platform.

  • Incorporation of the bone marker Carboxy-Terminal Telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma
    Leukemia, 2008
    Co-Authors: C Jakob, J Sterz, P Liebisch, M Mieth, J Rademacher, A Goerke, U Heider, C Fleissner, M Kaiser, I Von Metzler
    Abstract:

    Several prognostic markers, including parameters of tumor burden and cytogenetics, were adopted to identify high-risk patients in multiple myeloma (MM). Recently, the International Staging System (ISS), including β2-microglobulin (β2M) and albumin, was introduced for patients with symptomatic MM. As bone disease is a hallmark of MM, we investigated the prognostic impact of the bone resorption marker Carboxy-Terminal Telopeptide of type-1 collagen (ICTP) in combination with ISS, β2M, albumin, deletion of chromosome 13 and high-dose therapy (HDT) in 100 patients with newly diagnosed symptomatic MM. β2M alone, albumin alone, ISS, HDT, del(13q14) and ICTP were significant prognostic factors for overall survival (OS). In a multivariate analysis, ICTP was the most powerful prognostic factor (log-rank P

  • incorporation of the bone marker Carboxy Terminal Telopeptide of type 1 collagen improves prognostic information of the international staging system in newly diagnosed symptomatic multiple myeloma
    Leukemia, 2008
    Co-Authors: C Jakob, J Sterz, P Liebisch, M Mieth, J Rademacher, A Goerke, U Heider, C Fleissner, M Kaiser, I Von Metzler
    Abstract:

    Several prognostic markers, including parameters of tumor burden and cytogenetics, were adopted to identify high-risk patients in multiple myeloma (MM). Recently, the International Staging System (ISS), including β2-microglobulin (β2M) and albumin, was introduced for patients with symptomatic MM. As bone disease is a hallmark of MM, we investigated the prognostic impact of the bone resorption marker Carboxy-Terminal Telopeptide of type-1 collagen (ICTP) in combination with ISS, β2M, albumin, deletion of chromosome 13 and high-dose therapy (HDT) in 100 patients with newly diagnosed symptomatic MM. β2M alone, albumin alone, ISS, HDT, del(13q14) and ICTP were significant prognostic factors for overall survival (OS). In a multivariate analysis, ICTP was the most powerful prognostic factor (log-rank P<0.001, hazard ratio: ninefold increase). ICTP clearly separated two subgroups with a good and a worse prognosis within each of the three ISS stages (ISS I: P=0.027, ISS II: P=0.022, ISS III: P=0.013). Incorporation of ICTP in a combined ICTP-ISS score significantly (P<0.001) separated four risk groups with a 5-year OS rate of 95, 65, 46 and 32%, respectively. These data demonstrate for the first time that the inclusion of the collagen-I degradation product ICTP, as a biomarker of bone resorption, adds to the prognostic value of ISS.

Hiroshi Demura - One of the best experts on this subject based on the ideXlab platform.

  • Carboxy-Terminal propeptide of type 1 procollagen (P1CP) and Carboxy-Terminal Telopeptide of type 1 collagen (1CTP) as sensitive markers of bone metabolism in thyroid disease.
    Endocrine journal, 1996
    Co-Authors: Megumi Miyakawa, Toshio Tsushima, Hiroshi Demura
    Abstract:

    We measured serum levels of the Carboxy-Terminal propeptide of type 1 procollagen (P1CP) as a marker of bone formation and the Carboxy-Terminal Telopeptide of type 1 collagen (1CTP) as a marker of bone resorption by RIA in sera from 40 Graves' disease patients and 14 Hashimoto's disease patients before and during treatment. The serum P1CP levels of the untreated Graves' disease were significantly higher than in the controls (176.8 +/- 93.5 vs. 107 +/- 35 ng/ml, P < 0.01), and these levels decreased significantly during treatment with antithyroid drugs. There was a significant statistical correlation between serum P1CP levels and serum total alkaline-phosphatase activity (r = 0.61, P < 0.01) in the patients with Graves' disease and Hashimoto's disease as a whole. 1CTP levels were also significantly increased in untreated Graves' patients (6.5 +/- 2.8 compared with 2.7 +/- 1.1 ng/ml in normal subjects, P < 0.01). The P1CP/1CTP ratio, which reflects the relative ratio of bone formation to bone resorption, was lower than normal in untreated Graves' disease, but increased following the normalization of thyroid function. The results of this study suggest that the measurement of serum P1CP and 1CTP levels may be useful in evaluating bone metabolism in thyroid disease.